Official Journal of Research Center for Gastroenterology and Liver Diseases
Authors
Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons of enzyme increase in liver. In About 10 percent of patients with NAFLD, the disease progresses toward Non Alcoholic Steatohepatitis (NASH) and about one third of them may progress toward cirrhosis, liver dysfunction, and even hepatocellular carcinoma.
According to high prevalence of NAFLD and the fact that there is no consensus on treatment of this disease, the aim of this study was to assess the effects of metformin, pioglitazone, and silymarin on treatment of NAFLD.
Sixty-six patients with NAFLD who were presented in the Endocrinology and Metabolism clinic of Booali Hospital, Qazvin, Iran, were assigned randomly into three groups (n = 22). First group was treated by pioglitazone 15 mg/d, second group by metformin 500 mg/d, and third group by silymarin 140 mg/d. All patients underwent clinical and biochemical evaluations including weight, fasting blood sugar (FBS), lipid profiles, body mass index (BMI), aspartate aminotransferase (AST ), alanine aminotransferase (ALT), and serum insulin levels in pre- and post-intervention after eight-week follow up.
Before the treatment there was no significant difference between three groups with respect to average age, BMI and gender, FBS, lipid profile, AST, ALT, serum insulin level, and Homeostasis Model Assessment (HOMA) index for insulin resistance. After the intervention, a significant reduction was observed in average amount of FBS, lipid profile, ALT, AST, serum insulin level and HOMA index in three groups (P < 0.01). The most reduction in average FBS, TG, serum insulin level, and HOMA index was observed in pioglitazone group, the most reduction in average amount of cholesterol was seen in metformin group, and the most decrease in average amount of AST and ALT occurred in silymarin group.
These results suggest that all drugs are beneficial in improving biochemical indices in patients with NAFLD. Changes in AST and ALT in silymarin group were demonstrated more than that in other groups and the average difference between changes was significant between silymarin and metformin groups.
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, et al. The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial. Hepat Mon. 2013;13(5):e9270. doi: https://doi.org/10.5812/hepatmon.9270
Hajaghamohammadi A, Ziaee A, Rafiei R. The Efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Hepat Mon. 2008;8(3):. doi:
Hajiani E, Jalal Hashemi S, . COMPARISON OF THERAPEUTIC EFFECTS OF SILYMARIN AND VITAMIN E IN NONALCOHOLIC FATTY LIVER DISEASE: RESULTS OF AN OPEN-LABELE, PROSPECTIVE, RANDOMIZED STUDY. Jundishapur J Nat Pharm Prod. 2009;4(1):. doi:
Gharabally A, OBrien C, Acosta R. A Pilot Study of Pioglitazone for the Treatment of Non-Alcoholic Fatty Liver Disease. Hepat Mon. 2007;7(3):. doi:
Mai M, Wang Y, Wang D, Ruan Y, Mo B, et al. Effects of Silymarin Combined with Herbal Medicine on Th17/Treg Cell Imbalance and Inflammatory Response in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Hepat Mon. 2025;25(1):e157416. doi: https://doi.org/10.5812/hepatmon-157416
Last Update: 3 weeks ago
Last Update: 3 weeks ago
Last Update: 3 weeks ago
Last Update: 1 day ago
Last Update: 2 days ago
Last Update: 6 days ago
